Abstract
Bone tumours can be dissociated in two main categories: i) primary bone tumours (benign or malignant) including mainly osteosarcoma and other sarcomas. ii) and giant cell tumour and bone metastases originate from others cancer (Breast, prostate, kidney cancer, etc). These tumours are able to destroy or/and induce a new calcified matrix. However, the first step of bone tumour development is associated with an induction of bone resorption and the establishment of a vicious cycle between the osteoclasts and the tumour growth. Indeed, bone resorption contributes to the pathogenesis of bone tumour by the release of cytokines (IL6, TNFα) which govern the bone tumours development and which are trapped into the bone matrix. Bisphosphonates (BPs) are chemical compounds of P-C-P structure with a high affinity for bone hydroxyapatite crystals. Thus, they have been used as a carrier for radio nucleotides to develop novel approaches of bone imaging. BPs exert also indirect anti-tumour activities in vivo. Indeed, BPs directly interfere with the bone microenvironment and target osteoclasts, endothelial cells and immune cells (tumour-associated macrophages, γ9δ2 T cells). BPs induce tumour cell death in vitro and same activity is suspected in vivo. The present review summarizes the mechanisms of actions of BPs as well as their clinical interests in bone primary tumours.
Keywords: Bisphosphosphonates, primary bone tumors, sarcoma, giant cell tumor of bone, Bone Tumours, teosarcoma, sarcomas, vicious cycle, osteoclasts, bone hydroxyapatite crystals, malformations, chondroma, chondrosarcoma, osteoblastic lesions, osteoclastic-activating factors, osteoblast, osteoclast functions, malignant diseases, nitrogen-containing bisphosphonate, Giant cell tumours (GCT), osteoclastogenesis, reconstruction techniques, osteoclast apoptosis, risedronate, ibandronate, minodronate, Fas gene expression, edematous mitochondria, caspase-3 activation, annexin-V, fibrous dysplasia, osteosarcoma, chondroblastic, osteoblastic components, myeloma, prostate carcino-mas, opment, multidrug resistance (MDR), Dendritic cells, dog osteosarcoma devel
Current Pharmaceutical Design
Title: Therapeutic Approach of Primary Bone Tumours by Bisphosphonates
Volume: 16 Issue: 27
Author(s): G. Moriceau, B. Ory, B. Gobin, F. Verrecchia, F. Gouin, F. Blanchard, F. Redini and D. Heymann
Affiliation:
Keywords: Bisphosphosphonates, primary bone tumors, sarcoma, giant cell tumor of bone, Bone Tumours, teosarcoma, sarcomas, vicious cycle, osteoclasts, bone hydroxyapatite crystals, malformations, chondroma, chondrosarcoma, osteoblastic lesions, osteoclastic-activating factors, osteoblast, osteoclast functions, malignant diseases, nitrogen-containing bisphosphonate, Giant cell tumours (GCT), osteoclastogenesis, reconstruction techniques, osteoclast apoptosis, risedronate, ibandronate, minodronate, Fas gene expression, edematous mitochondria, caspase-3 activation, annexin-V, fibrous dysplasia, osteosarcoma, chondroblastic, osteoblastic components, myeloma, prostate carcino-mas, opment, multidrug resistance (MDR), Dendritic cells, dog osteosarcoma devel
Abstract: Bone tumours can be dissociated in two main categories: i) primary bone tumours (benign or malignant) including mainly osteosarcoma and other sarcomas. ii) and giant cell tumour and bone metastases originate from others cancer (Breast, prostate, kidney cancer, etc). These tumours are able to destroy or/and induce a new calcified matrix. However, the first step of bone tumour development is associated with an induction of bone resorption and the establishment of a vicious cycle between the osteoclasts and the tumour growth. Indeed, bone resorption contributes to the pathogenesis of bone tumour by the release of cytokines (IL6, TNFα) which govern the bone tumours development and which are trapped into the bone matrix. Bisphosphonates (BPs) are chemical compounds of P-C-P structure with a high affinity for bone hydroxyapatite crystals. Thus, they have been used as a carrier for radio nucleotides to develop novel approaches of bone imaging. BPs exert also indirect anti-tumour activities in vivo. Indeed, BPs directly interfere with the bone microenvironment and target osteoclasts, endothelial cells and immune cells (tumour-associated macrophages, γ9δ2 T cells). BPs induce tumour cell death in vitro and same activity is suspected in vivo. The present review summarizes the mechanisms of actions of BPs as well as their clinical interests in bone primary tumours.
Export Options
About this article
Cite this article as:
Moriceau G., Ory B., Gobin B., Verrecchia F., Gouin F., Blanchard F., Redini F. and Heymann D., Therapeutic Approach of Primary Bone Tumours by Bisphosphonates, Current Pharmaceutical Design 2010; 16 (27) . https://dx.doi.org/10.2174/138161210793563554
DOI https://dx.doi.org/10.2174/138161210793563554 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MicroRNAs and their Implications in CD4+ T-cells,
Oligodendrocytes and Dendritic Cells in Multiple Sclerosis
Pathogenesis
Current Molecular Medicine Therapeutics Based on microRNA: A New Approach for Liver Cancer
Current Genomics A Therapeutic Potential of Animal β-hairpin Antimicrobial Peptides
Current Medicinal Chemistry Targeting Interleukin-1β for Pain
CNS & Neurological Disorders - Drug Targets Formulation Strategies and Particle Engineering Technologies for Pulmonary Delivery of Biopharmaceuticals
Current Pharmaceutical Design Assessing Glutamatergic Function and Dysfunction in Peripheral Tissues
Current Medicinal Chemistry Signal Transducer and Activator of Transcription Protein 3 (STAT3): An Update on its Direct Inhibitors as Promising Anticancer Agents
Current Medicinal Chemistry Prospects for Anti-Neoplastic Therapies Based on Telomere Biology
Current Cancer Drug Targets Src Kinase Inhibitors: An Update on Patented Compounds
Current Medicinal Chemistry The Dual Role of Tumor Necrosis Factor (TNF) in Cancer Biology
Current Medicinal Chemistry Preface
Current Cancer Drug Targets Induction of Thyroid Neoplasm Following Plant Medicine Marine Algae (Sargassum): A Rare Case and Review of the Literature
Current Pharmaceutical Biotechnology Role of Caspases, Bax and Bcl-2 in Chrysin-Induced Apoptosis in the A549 Human Lung Adenocarcinoma Epithelial Cells
Anti-Cancer Agents in Medicinal Chemistry MicroRNA and Bone Tumor: To Up Date
Current Signal Transduction Therapy A Systematic Review of Selected Musculoskeletal Late Effects in Survivors of Childhood Cancer
Current Pediatric Reviews Recent Development in Fluorescent Probes for Copper Ion Detection
Current Topics in Medicinal Chemistry Efficacy of Pegylated Lyposomal Anthracyclines and of Intra-Arterial Carboplatin and Doxorubicin Combined with Local Hyperthermia in a Case of Malignant Endovascular Papillary Angioendothelioma
Current Drug Delivery Targeting Sugar Uptake and Metabolism for Cancer Identification and Therapy: An Overview
Current Topics in Medicinal Chemistry Function of miRNA in Controlling Drug Resistance of Human Cancers
Current Drug Targets Updates of mTOR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry